All News

Found 2,404 articles

• Former Epizyme CEO Helms Fulcrum Therapeutics; New Startup Banks $55 Million Series A

  7/19/2016

• Precision NanoSystems Launches Innovative Product To Support mRNA And CRISPR/Cas9 Therapeutic Development

  7/19/2016

• EBD Group Release: Key Life Science Industry Thought Leaders And New One-Day Programs Elevate Offerings At BioPharm America 2016

  7/15/2016

• Evotec AG Enters Licence Agreement For Access To CRISPR-CAS9 Gene Editing Technology

  7/6/2016

• First-Ever CRISPR Trial Points to Looming Problems

  6/30/2016

• Bio-Rad Release: New Method To Assess Effectiveness Of Genome-Editing Technologies

  6/30/2016

• CRISPR Reels in Another $38 Million Series B Financing

  6/24/2016

• 31-Year-Old Rachel Haurwitz Helms Hot CRISPR-Based Biotech Firm Caribou Biosciences

  6/23/2016

• Frost & Sullivan Release: Life Science Disruptive Technologies And Emerging Trends Spur Growth Opportunities Throughout The Industry

  6/23/2016

• Silicon Valley Tech Titan Sean Parker to Back First CRISPR Test

  6/22/2016

• CRISPR And Anagenesis Biotechnologies Announce Strategic In-Licensing And Collaboration Agreement To Develop CRISPR/Cas9-Based Cell Therapies For Muscle Diseases

  6/8/2016

• Lonza Inc.’s 4D-NucleofectorTM LV Unit Delivers Closed, Optimized, Larger-Scale Transfection

  6/8/2016

• Avellino Labs Announces Collaboration With Ulster University On Cornea Gene Therapy Program

  6/7/2016

• Frost & Sullivan Release: Disruptive Technologies And Emerging Trends Drive Life Science Transformation

  6/7/2016

• Top Biotech Startups are Looking for You at BIO 2016 in San Francisco

  6/6/2016

• Applied StemCell, Inc. Secures $19 Million In Series D Financing

  6/6/2016

• Twist Bioscience And Desktop Genetics To Offer Integrated Design Services And DNA Synthesis For Gene Editing Research

  6/1/2016

• nLife Therapeutics Appoints Dr. Errol B. De Souza As Executive Chairman

  6/1/2016

• ERS Genomics Appoints Eric Rhodes as Chief Executive Officer

  6/1/2016

• Abeona Therapeutics Doses First Patient In Phase 1/2 Trial With ABO-102 Gene Therapy For Patients With Sanfilippo Syndrome Type A (MPS IIIA)

  5/18/2016